Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $33.67

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned an average recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $33.67.

Several brokerages recently issued reports on ENGN. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Morgan Stanley reiterated an “overweight” rating and set a $40.00 price target on shares of enGene in a report on Wednesday, September 11th.

enGene Price Performance

Shares of ENGN opened at $6.05 on Friday. enGene has a 52-week low of $4.42 and a 52-week high of $43.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. The business’s 50 day moving average price is $7.00 and its two-hundred day moving average price is $10.82. The firm has a market cap of $267.20 million, a PE ratio of -3.52 and a beta of -0.68.

enGene (NASDAQ:ENGN) last issued its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. On average, equities analysts anticipate that enGene will post -1.64 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ENGN. BVF Inc. IL bought a new position in enGene in the 4th quarter valued at $20,777,000. Omega Fund Management LLC bought a new position in enGene in the 4th quarter valued at $10,441,000. Janus Henderson Group PLC bought a new position in enGene in the 1st quarter valued at $17,095,000. SR One Capital Management LP bought a new position in enGene in the 2nd quarter valued at $4,715,000. Finally, Logos Global Management LP grew its stake in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares during the period. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.